AU · rank #16 · 2026-09-04
CORT
NASDAQ · $11.94B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.187 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$1.20 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.171 |
| Analyst upside Consensus target $141.00 | +25.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +39.68% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +98.3% |
| 52w high | $126.38 |
| Market cap (USD) | $11.94B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Corcept Therapeutics is a commercial-stage biopharma generating ~$1B+ annualized revenue from cortisol-modulating drugs Korlym and newly launched Lifyorli, targeting Cushing's syndrome and oncology.
Rationale
The analyst_upside_pct of 25% is credible given 32% YoY revenue growth, a raised $1.1–1.2B guidance, 100% revision agreement among analysts, and a 535% earnings surprise that drove meaningful EPS estimate lifts over 30–90 days.
Material risks
- 1Analyst coverage is thin (only 4 analysts) with net downgrades over 90 days and zero target raises in 30 days, and the 81.6% target dispersion signals deep disagreement on fair value that could cap re-rating.
- 2Revenue concentration in Korlym/authorized generic plus early-stage Lifyorli leaves CORT exposed to a single competitive cortisol modulator or payer pushback that could rapidly compress the growth narrative underpinning the upside target.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.